CYTARABINE

Cytarabine

Composition: eachvial contains:  

active substance: cytarabine – 1000 mg, 100 mg.

Therapeutic indications

• Lymphoblast and myeloblast leukemia.
• Chronic myeloleukemia.
• Erythroleukemia, lymphogranulomatosis.
• Non-Hodgkin’s lymphoma.
• Syndrome of bone marrow dysplasia.

The Cytarabine high-dose therapy is applied within the induction and consolidation programs under primary acute lymphoblast and myeloblast leukemia; under secondary leukemia developed either after the preceding cytostatic and/or beam therapy or as a result of the MDS transformation; under primarily resistant forms of acute leukemia; under resistant relapses of acute leukemia; under a blast crisis of chronic myeloleukemia; under resistant forms of highly malignant Hodgkin’s and non-Hodgkin’s lymphomas.

	АТС code
	L01BC01
	Pharmaceutical form
	lyophilized powder for solution for injection / solution for injection 20 mg/ml
	Storage conditions
	Store in protected from light place at temperature below 25°C.